Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Measles
Research from Mayo Clinic provides new data on measles
October 14th, 2008
"Gliomas have a dismal prognosis, with the median survival of patients with the most common histology, glioblastoma multiforme, being only 12-15 months. Development of novel therapeutic agents is urgently needed," investigators in the United States report. "We have previously demonstrated that oncolytic measles virus strains derived from the Edmonston vaccine lineage have significant antitumor activity against gliomas [Phuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S., Teneyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J., Galanis, E. C. (2003). Cancer. Res. 63, 2462-2469]. MV-CEA is an Edmonston vaccine lineage measles virus strain engineered to...
Source: Cancer Weekly (2008-10-14)
|
